Product news

Share this article:
The FDA has approved Sucampo Pharmaceuticals' supplemental NDA for Amitiza (lubiprostone) to treat irritable bowel syndrome with constipation in women 18 years of age or older. As a result of the approval, Sucampo Pharmaceuticals will receive a development milestone payment of $50 million from Takeda in accordance a prior licensing agreement. Sucampo Pharmaceuticals and Takeda will jointly market Amitiza in the US and Canada. 
 
The FDA approved Watson Pharmaceuticals' Mixject, a new delivery system for Trelstar (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer.
Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.